Pfizer Names Zuellig As New Distributor In Malaysia
Pfizer Malaysia, a wholly-owned subsidiary of Pfizer in the USA, hasappointed Zuellig Pharma as sole distributor for all its pharmaceutical products, according to Pfizer's managing director, Radzmi Rahmat, who said at a press conference that distribution will be left entirely to Zuellig. The Malaysian company is a wholly-owned subsidiary of Gold Coin Ltd.
Zuellig Pharma's chief executive, Andre Keller, added that Pfizer hopes to be the leading pharmaceutical company in Malaysia in three years by launching and distributing more new products.
Pfizer Malaysia forecasts a turnover of 40 million ringgit ($9.5 million), while Zuellig, which represents 40 multinational pharmaceutical companies, expects turnover of 350 million ringgit for the current year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze